secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193125-22-280757
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q3 revenue $4.2M; Desai to Executive Chairman, Delaney named CEO
--------------------------------------------------------------------------------

- Net product sales of FYARRO $4.2M in Q3 2022, up 24% from Q2; net loss $14.5M (vs $87.1M in Q3 2021).
- Cash $183M as of Sep 30, 2022; cash runway extended into 2025 after $72.5M PIPE financing.
- Founder/CEO Neil Desai appointed Executive Chairman; COO Brendan Delaney succeeds as President & CEO effective Jan 1, 2023.
- Delaney receives $624K base salary, 60% bonus target, option for 150K shares; Board expanded to 8.
- PRECISION 1 trial on track for preliminary data H1 2023; Mirati collaboration on adagrasib/nab-sirolimus combo expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/0001193125-22-280757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312522280757/d317786d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-280757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer